• 1
    Merkesdal S, Ruof J, Mittendorf T, Mau W, Zeidler H. Health economics research in the area of chronic polyarthritis. Z Rheumatol 2002; 61: 219. In German.
  • 2
    Ruof J, Huelsemann JL, Stucki G. Evaluation of costs in rheumatic diseases: a literature review. Curr Opin Rheumatol 1999; 11: 1049.
  • 3
    Mittendorf T, Merkesdal S, Huelsemann JL, von der Schulenburg JM, Zeidler H, Ruof J. Implementing standardized cost categories within economic evaluations in musculoskeletal diseases. Eur J Health Econ 2003; 4: 439.
  • 4
    Ruof J, Merkesdal S, Huelsemann JL, Schoeffski O, Maetzel A, Mau W, et al. Cost assessment instrument in rheumatology: evaluation of applied instrument characteristics. J Rheumatol 2001; 28: 6625.
  • 5
    Clarke AE, Esdaile JM, Bloch DA, Lacaille D, Danoff DS, Fries JF. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993; 36: 154859.
  • 6
    Guzman J, Pelosi P, Bombardier C. Capturing health care utilization after occupational low-back pain: development of an interviewer-administered questionnaire. J Clin Epidemiol 1999; 52: 41927.
  • 7
    Goossens ME, Rutten-van Molken MP, Vlaeyen JW, van der Linden SM. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol 2000; 53: 68895.
  • 8
    Ritter PL, Stewart AL, Kaymaz H, Sobel DS, Block DA, Lorig KR. Self-reports of health care utilization compared to provider records. J Clin Epidemiol 2001; 54: 13641.
  • 9
    Ruof J, Huelsemann JL, Mittendorf T, Handelmann S, von der Schulenburg JM, Zeidler H, et al. Patient-reported health care utilization in rheumatoid arthritis: what level of detail is required? Arthritis Rheum 2004; 51: 77481.
  • 10
    Hulsemann JL, Mattussek S, Hennig H, Stucki G. Quality management of treatment of rheumatoid arthritis in a rheumatological setting. Z Arztl Fortbild Qualitatssich 2003; 97: 38390. In German.
  • 11
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 12
    Merkesdal S, Ruof J, Huelsemann JL, Schoeffski O, Maetzel A, Mau W, et al. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. J Rheumatol 2001; 28: 65761.
  • 13
    Schoeffski O, Glaser P, Schulenburg JM, Graf VD. Health economic evaluation. New York: Springer-Verlag; 1998.
  • 14
    Hannoveraner Konsensus Gruppe. Deutsche empfehlungen zur gesundheitsökonomischen evaluation: Revidierte Fassung des Hannoveraner Konsens. Gesundh okon Qual manag 1999; 4: A625.
  • 15
    Institute for labour market- and vocational research Germany: Unemployed and unemployment rates (2002) Statistisches Bundesamt, Pressestelle; 2002.
  • 16
    Koopmanschap MA: Complementary analyses in economic evaluation of health care [dissertation]. Rotterdam (The Netherlands): Erasmus University; 1994.
  • 17
    Bundesanstalt fuer Arbeit: Strukturanalyse 1993, Nürnberg, Germany: Statistisches Bundesamt, Pressestelle; 1994.
  • 18
    Statistisches Bundesamt. Statistical Yearbook 2001 for the Federal Republic of Germany. Wiesbaden: Metzler Poeschel; 2001.
  • 19
    Merkesdal S, Ruof J, Mittendorf T, Zeidler H, Mau W. Indirect medical costs in the first three years of rheumatoid arthritis: comparison of current methodological approaches. Expert Rev Pharmacoeconomics Outcomes Res 2002; 2: 8994.
  • 20
    Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wong WK, Bulpitt KJ, et al, and the Western Consortium of Practicing Rheumatologists. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol 2000; 27: 115663.
  • 21
    McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35: 78190.
  • 22
    Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 34756.
  • 23
    Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997; 24: 105160.
  • 24
    Magnusson S. Treatment of rheumatoid arthritis: does it affect society′s cost for the disease? Br J Rheumatol 1996; 35: 7915.
  • 25
    Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001; 44: 52834.